Shire partnered with Shionogi to co-develop and co-commercialize Shire's ADHD products Vyvanse and Intuniv extended release in Japan

Shire plc

Ireland / Mid-Cap Biopharma ($1-$50 billion)

$17,804.1m on 11/18/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Shionogi & Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced